Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
KeAi Communications Co., Ltd.
2018
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|